A comprehensive view of Rx-to-OTC Switch. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Government & Public Policy Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Raymond James: Perrigo's acquisition of HRA Pharma may be overlooked by investors, as HRA is expected to file application for OTC birth control pill by end-2022; in light of Roe v. Wade ruling, potential annual sales of HRA pill could hit US$100M-US$200M

Perrigo receives final FDA approval for OTC use of the Nasonex 24HR Allergy, previously available via prescription; Perrigo expects to begin offering the product later in 2022

Allergan announces LASTACAFT antihistamine eye drops with alcaftadine ophthalmic solution 0.25% now available as OTC product in 5 mL multidose bottle with 60 day supply; itchy eyes affect 40% of Americans with ocular allergies

Fitch: UK's OTC medicine market is a pioneer in terms of switching drug status from prescription to OTC, and is among most developed across Europe and globally; UK's OTC segment share of total market expected to rise to 9.1% by 2031 from 7.9% in 2021

Study shows significant decrease in patients reporting nasal allergy symptoms during healthcare visits, decrease in per-person cost after switch of nasal corticosteroids to OTC status; recent conference shows increased conversation around Rx-to-OTC switch

Ask us about our Government & Public Policy market view

Trending Chart

Interactive chart with headline count